Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashley Wallace-Tucker

Optometrist Houston, TX Doctor of Optometry

NPI 1407169824 CMS profile 659461

4401 Martin Luther King Blvd, Mailcode H2020, Houston, TX 77204

Open in the dashboard

General payments

$546,585

585 records reported · program years 2019–2025

Research payments

$61,875

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$21,610 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Ashley Wallace-Tucker of Houston, TX is reported in the CMS Open Payments database as having received $546,585 across 585 general payments and $61,875 in research payments paid to them. Separately, studies naming them as principal investigator received $21,610 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $111,117 113
2024 General $107,214 113
2023 General $113,728 123
2023 Research $27,515 1
2022 General $171,770 91
2022 Research $34,360 1
2021 General $31,369 60
2020 General $5,775 19
2019 General $5,612 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Wallace-Tucker
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Ashley Wallace-Tucker were reported at $111,117. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Ashley Wallace-Tucker Optometrist median Middle half National median
2019 $5,612 $159 $67–$371 $163
2020 $5,775 $72 $29–$165 $114
2021 $31,369 $125 $46–$292 $132
2022 $171,770 $162 $66–$374 $149
2023 $113,728 $177 $72–$406 $160
2024 $107,214 $188 $77–$427 $164
2025 $111,117 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Visioneering Technologies, Inc. $361,418 51 payments
  2. CooperVision Inc. $87,687 197 payments
  3. Bausch & Lomb Americas Inc. $41,089 60 payments
  4. Alcon Vision LLC $17,974 95 payments
  5. Johnson & Johnson Vision Care, Inc. $16,148 112 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $11,404 20 payments
  7. Topcon Medical Systems, Inc. $8,134 18 payments
  8. Visionary Optics LLC $1,710 1 payment
  9. Tarsus Pharmaceuticals, Inc. $304 7 payments
  10. Glaukos Corporation $184 2 payments
  11. Other $533 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $442,112 167 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $37,450 22 payments
  3. Consulting Fee $32,882 66 payments
  4. Travel and Lodging $22,146 109 payments
  5. Food and Beverage $5,035 215 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,000 2 payments
  7. Honoraria $2,250 3 payments
  8. Gift $1,710 1 payment
Products named General payments · program years 2019–2025
  1. MiSight Contact Lens $63,107 71 payments
  2. ZEN LENS $25,602 32 payments
  3. ZENLENS $22,312 25 payments
  4. Clariti Contact Lens $16,162 76 payments
  5. Acuvue $16,097 109 payments
  6. AIR OPTIX $14,747 72 payments
  7. Biofinity Contact Lens $2,019 23 payments
  8. CVI Contact Lens $1,800 1 payment
  9. DAILIES $1,590 11 payments
  10. Paragon CRT $1,475 6 payments
  11. Other $6,144 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. CooperVision Inc. $61,875 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

23

Median for Optometry: 120

Drug cost

$213

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 23 $213

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$10,925

Medicare's payments for the services billed

Medicare patients

107

Average age 73

Services billed

148

71 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 48%
Ischemic heart disease 24%
Diabetes 17%
Depression 14%
Osteoporosis 14%
Chronic kidney disease 13%
Heart failure 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $97
$97 — —
MIEBO
  • Bausch & Lomb Americas Inc. $58
$58 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $58
$58 — —
VEVYE
  • Harrow Eye, LLC $35
$35 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

587 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record